Patient Name	Mrs. MADHU LATA MEENA	Lab No	4032314
UHID	40013498	Collection Date	26/04/2024 10:11AM
Age/Gender IP/OP Location	30 Yrs/Female	Receiving Date	26/04/2024 10:15AM
	O-OPD	Report Date	26/04/2024 11:34AM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	9414692856		

### **BIOCHEMISTRY**

Test Name	Result	Unit	Biological Ref. Range	
BLOOD GLUCOSE (FASTING)				Sample: Fl. Plasma
BLOOD GLUCOSE (FASTING)	98	mg/dl	71 - 109	

Method: Hexokinase assay.

Interpretation: -Diagnosis and monitoring of treatment in diabetes mellitus and evaluation of carbohydrate metabolism in various diseases

**THYROID T3 T4 TSH** Sample: Serum Т3 0.970 - 1.690 1.210 ng/mL T4 8.91 ug/dl 5.53 - 11.00 TSH 2.84 μIU/mL 0.40 - 4.05

T3:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T3 is utilized in thediagnosis of T3-hyperthyroidism the detection of early stages ofhyperthyroidism and for indicating a diagnosis of thyrotoxicosis factitia.

T4:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T4 assay employs acompetitive test principle with an antibody specifically directed against T4.

TSH - THYROID STIMULATING HORMONE :- ElectroChemiLuminescenceImmunoAssay - ECLIA

Interpretation:-The determination of TSH serves as theinitial test in thyroid diagnostics. Even very slight changes in the concentrations of the free thyroid hormones bring about much greater opposite changes in the TSH levels.

LFT (LIVER FUNCTION TEST)				Sample: Serum
BILIRUBIN TOTAL	0.50	mg/dl	0.00 - 1.20	
BILIRUBIN INDIRECT	0.31	mg/dl	0.20 - 1.00	
BILIRUBIN DIRECT	0.19	mg/dl	0.00 - 0.30	
SGOT	20.0	U/L	0.0 - 32.0	
SGPT	16.9	U/L	0.0 - 33.0	

U/L

**RESULT ENTERED BY: SUNIL EHS** 

Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

Page: 1 Of 9

Patient Name UHID	Mrs. MADHU LATA MEENA 40013498	Lab No Collection Date	4032314 26/04/2024 10:11AM	
Age/Gender	30 Yrs/Female	Receiving Date	26/04/2024 10:15AM	
IP/OP Location	O-OPD	Report Date	26/04/2024 11:34AM	
Referred By	Dr. EHS CONSULTANT	Report Status	Final	
Mobile No.	9414692856			

		BIOCHEMISTRY	
TOTAL PROTEIN	7.1	g/dl	6.6 - 8.7
ALBUMIN	4.6	g/dl	3.5 - 5.2
GLOBULIN	2.5		1.8 - 3.6
ALKALINE PHOSPHATASE	79	U/L	35 - 104
A/G RATIO	1.8	Ratio	1.5 - 2.5
GGTP	13.0	U/L	0.0 - 40.0

BILIRUBIN TOTAL :- Method: DPD assay. Interpretation:-Total Bilirubin measurements are used in the diagnosis and treatment of various liver diseases, and of haemolytic and metabolic disorders in adults and newborns. Both obstruction damage to hepatocellular structive.

BILIRUBIN DIRECT :- Method: Diazo method Interpretation:-Determinations of direct bilirubin measure mainly conjugated,

saturations of direct bilitubin.

SGOT - AST :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGOT(AST) measurements are used in the diagnosis and treatment of certain types of liver and heart disease.

SGPT - ALT :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGPT(ALT) Ratio Is Used For Differential Diagnosis In Liver Diseases.

TOTAL PROTEINS :- Method: Biuret colorimetric assay. Interpretation:-Total protein measurements are used in the diagnosis and treatment of a variety of liver and kidney diseases and bone marrow as well as metabolic and nutritional disorder.

ALBUMIN: - Method: Colorimetric (BCP) assay. Interpretation: -For Diagnosis and monitoring of liver diseases, e.g. liver cirrhosis, nutritional status.

ALKALINE PHOSPHATASE :- Method: Colorimetric assay according to IFCC. Interpretation:-Elevated serum ALT is found in hepatitis, cirrhosis, obstructive jaundice, carcinoma of the liver, and chronic alcohol abuse. ALT is only slightly elevated in patients who have an uncomplicated myocardial infarction. **GGTP-GAMMA GLUTAMYL TRANSPEPTIDASE**:- Method: Enzymetic colorimetric assay. Interpretation:-y-glutamyltransferase is used in the diagnosis and monitoring of hepatobiliary disease. Enzymatic activity of GGT is often the only parameter with increased values when testing for such diseases and is one of the most sensitive indicator known.

#### LIPID PROFILE

TOTAL CHOLESTEROL	157		<200 mg/dl :- Desirable 200-240 mg/dl :- Borderline >240 mg/dl :- High
HDL CHOLESTEROL	61.8		High Risk :-<40 mg/dl (Male), <40 mg/dl (Female) Low Risk :->=60 mg/dl (Male), >=60 mg/dl (Female)
LDL CHOLESTEROL	88.5		Optimal :- <100 mg/dl Near or Above Optimal :- 100-129 mg/dl Borderline :- 130-159 mg/dl High :- 160-189 mg/dl Very High :- >190 mg/dl
CHOLESTERO VLDL	18	mg/dl	10 - 50

**RESULT ENTERED BY: SUNIL EHS** 

Dr. ABHINAY VERMA

MBBS|MD|INCHARGE PATHOLOGY

Patient Name	Mrs. MADHU LATA MEENA	Lab No	4032314
UHID	40013498	Collection Date	26/04/2024 10:11AM
Age/Gender IP/OP Location	30 Yrs/Female	Receiving Date	26/04/2024 10:15AM
	O-OPD	Report Date	26/04/2024 11:34AM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	9414692856		

## **BIOCHEMISTRY**

TRIGLYCERIDES 88 Normal:-<150 mg/dl

Border Line:- 150 - 199 mg/dl High :- 200 - 499 mg/dl Very high :- > 500 mg/dl

CHOLESTEROL/HDL RATIO 3 %

CHOLESTEROL TOTAL: - Method: CHOD-PAP enzymatic colorimetric assay. Interpretation: The determination of the individual total cholesterol (TC) level is used for screening purposes while for a better risk assessment it is necessary to measure additionally lipid & lipoprotein metabolic disorders. HDL CHOLESTEROL: - Method: Homogenous enzymetic colorimetric method. Interpretation: -HDL-cholesterol has a protective against coronary heart disease, while reduced HDL-cholesterol concentrations, particularly in conjunction with elevated triglycerides, increase the cardiovascular disease. LDL CHOLESTEROL: - Method: Homogenous enzymatic colorimetric assay. Interpretation: -LDL play a key role in causing and influencing the progression of atherosclerosis and in particular coronary sclerosis. The LDL are derived form VLDL rich in TG by the action of various lipolytic enzymes and are synthesized in the liver. CHOLESTEROL VLDL: - Method: VLDL Calculative

TRIGITYCERIDES: - Method: GPO-PAP enzymatic colorimetric assay. Interpretation:-High triglycerde levels also occur in various diseases of liver, kidneys and pancreas. DM, nephrosis, liver obstruction. CHOLESTEROL/HDL RATIO: - Method: Cholesterol/HDL Ratio Calculative

Sample: Serum

UREA	18.30	mg/dl	16.60 - 48.50
BUN	9	mg/dl	6 - 20
CREATININE	0.67	mg/dl	0.50 - 0.90
SODIUM	139	mmol/L	136 - 145
POTASSIUM	4.18	mmol/L	3.50 - 5.50
CHLORIDE	105.0	mmol/L	98 - 107
URIC ACID	3.7	mg/dl	2.4 - 5.7
CALCIUM	9.43	mg/dl	8.60 - 10.00

RESULT ENTERED BY : SUNIL EHS

Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

Page: 3 Of 9

Mrs. MADHU LATA MEENA Lab No **Patient Name** 4032314 UHID **Collection Date** 26/04/2024 10:11AM 40013498 26/04/2024 10:15AM Age/Gender **Receiving Date** 30 Yrs/Female Report Date O-OPD **IP/OP Location** 26/04/2024 11:34AM

Referred By Dr. EHS CONSULTANT Report Status Final

Mobile No. 9414692856

#### **BIOCHEMISTRY**

CREATININE - SERUM :- Method:-Jaffe method, Interpretation:-To differentiate acute and chronic kidneydisease.
URIC ACID :- Method: Enzymatic colorimetric assay. Interpretation:- Elevated blood concentrations of uricacid are renal diseases with decreased excretion of waste products, starvation, drug abuse and increased alcohol consume.
SODIUM:- Method: ISE electrode. Interpretation:-Decrease: Prolonged vomiting or diarrhea, diminished reabsorption in the kidney and excessive fluid retention. Increase: excessive fluid loss, high salt intake and kidney reabsorption.
POTASSIUM:- Method: ISE electrode. Intrpretation:-Low level: Intake excessive loss formbodydue to diarrhea, vomiting

renal failure, High level: Dehydration, shock severe burns, DKA, renalfailure.

CHLORIDE - SERUM: Method: ISE electrode. Interpretation: Decrease: reduced dietary intake, prolonged vomiting and reduced renal reabsorption as well as forms of acidosisand alkalosis.

Increase: dehydration, kidney failure, some form ofacidosis, high dietary or parenteral chloride intake, and salicylate poisoning.

UREA:- Method: Urease/GLDH kinetic assay. Interpretation:-Elevations in blood urea nitrogenconcentration are seen in inadequate renal perfusion, shock, diminished bloodvolume, chronic nephritis, nephrosclerosis, tubular necrosis, glomerularnephritis and UTI.

CALCIUM TOTAL: - Method: O-Cresolphthaleine complexone. Interpretation:-Increase in serum PTH or vit-D are usually associated with hypercalcemia. Increased serum calcium levels may also be observed in multiple myeloma and other neoplastic diseases. Hypocalcemia may

be observed in hypoparathyroidism, nephrosis, and pancreatitis.

Sample: WHOLE BLOOD EDTA

HBA1C 5.1 % < 5.7% Nondiabetic

5.7-6.4% Pre-diabetic > 6.4% Indicate Diabetes

Known Diabetic Patients
< 7 % Excellent Control
7 - 8 % Good Control
> 8 % Poor Control

Method: - Turbidimetric inhibition immunoassay (TINIA), Interpretation:-Monitoring long term glycemic control, testing every 3 to 4 months is generally sufficient. The approximate relationship between HbAlC and mean blood glucose values during the preceding 2 to 3 months.

RESULT ENTERED BY : SUNIL EHS

Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

Page: 4 Of 9

**Patient Name** Mrs. MADHU LATA MEENA Lab No 4032314 UHID 40013498 **Collection Date** 26/04/2024 10:11AM 26/04/2024 10:15AM Age/Gender **Receiving Date** 30 Yrs/Female **Report Date IP/OP Location** O-OPD 26/04/2024 11:34AM

**Referred By** Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 9414692856

## **BLOOD BANK INVESTIGATION**

**Biological Ref. Range Test Name** Result Unit

**BLOOD GROUPING** "B" Rh Positive

1. Both forward and reverse grouping performed.
2. Test conducted on EDTA whole blood.

**RESULT ENTERED BY: SUNIL EHS** 

Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

**Patient Name** Lab No 4032314 Mrs. MADHU LATA MEENA **Collection Date** 26/04/2024 10:11AM UHID 40013498 26/04/2024 10:15AM Age/Gender **Receiving Date** 30 Yrs/Female **Report Date** O-OPD **IP/OP Location** 26/04/2024 11:34AM

**Referred By** Dr. EHS CONSULTANT **Report Status** Final

NIL

**Mobile No.** 9414692856

## **CLINICAL PATHOLOGY**

Test Name	Result	Unit	Biological Ref. Range	
URINE SUGAR (RANDOM)				Sample: Urine
URINE SUGAR (RANDOM)	NEGATIVE		NEGATIVE	
				Sample: Urine
PHYSICAL EXAMINATION				
VOLUME	20	ml		
COLOUR	PALE YELLOW		P YELLOW	
APPEARANCE	CLEAR		CLEAR	
CHEMICAL EXAMINATION				
PH	6.0		5.5 - 7.0	
SPECIFIC GRAVITY	1.000		1.016-1.022	
PROTEIN	NEGATIVE		NEGATIVE	
SUGAR	NEGATIVE		NEGATIVE	
BILIRUBIN	NEGATIVE		NEGATIVE	
BLOOD	NEGATIVE			
KETONES	NEGATIVE		NEGATIVE	
NITRITE	NEGATIVE		NEGATIVE	
UROBILINOGEN	NEGATIVE		NEGATIVE	
LEUCOCYTE	NEGATIVE		NEGATIVE	
MICROSCOPIC EXAMINATION				
WBCS/HPF	1-2	/hpf	0 - 3	
RBCS/HPF	0-0	/hpf	0 - 2	
EPITHELIAL CELLS/HPF	2-3	/hpf	0 - 1	
CASTS	NIL		NIL	
CRYSTALS	NIL		NIL	
BACTERIA	NIL		NIL	

NIL

RESULT ENTERED BY : SUNIL EHS

Dr. ABHINAY VERMA

**OHTERS** 

MBBS | MD | INCHARGE PATHOLOGY

Mrs. MADHU LATA MEENA **Patient Name** Lab No 4032314 UHID 40013498 **Collection Date** 26/04/2024 10:11AM 26/04/2024 10:15AM Age/Gender **Receiving Date** 30 Yrs/Female **Report Date IP/OP Location** O-OPD 26/04/2024 11:34AM **Referred By** Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 9414692856

Methodology:-Glucose: GOD-POD, Bilirubin: Diazo-Azo-coupling reaction with a diazonium, Ketone: Nitro Pruside reaction, Specific Gravity: Proton release from ions, Blood: Psuedo-Peroxidase activity oh Haem moiety, pH: Methye Red-Bromothymol Blue (Double indicator system), Protein: H+ Release by buffer, microscopic & chemical method. interpretation: Diagnosis of Kidney function, UTI, Presence of Protein, Glucoses, Blood. Vocubulary syntax: Kit insert

**RESULT ENTERED BY: SUNIL EHS** 

**Patient Name** Mrs. MADHU LATA MEENA Lab No 4032314 UHID 40013498 **Collection Date** 26/04/2024 10:11AM Age/Gender 26/04/2024 10:15AM **Receiving Date** 30 Yrs/Female Report Date **IP/OP Location** O-OPD 26/04/2024 11:34AM Dr. EHS CONSULTANT Final

**Referred By Report Status** 

Mobile No. 9414692856

### **HEMATOLOGY**

Test Name	Result	Unit	Biological Ref. Range
CBC (COMPLETE BLOOD COUNT)			Sample: WHOLE BLOOD EDTA
HAEMOGLOBIN	12.1	g/dl	12.0 - 15.0
PACKED CELL VOLUME(PCV)	37.9	%	36.0 - 46.0
MCV	99.2 H	fl	82 - 92
MCH	31.7	pg	27 - 32
MCHC	31.9 L	g/dl	32 - 36
RBC COUNT	3.82	millions/cu.mm	3.80 - 4.80
TLC (TOTAL WBC COUNT)	4.95	10^3/ uL	4 - 10
DIFFERENTIAL LEUCOCYTE COUNT			
NEUTROPHILS	66.1	%	40 - 80
LYMPHOCYTE	24.4	%	20 - 40
EOSINOPHILS	5.1	%	1 - 6
BASOPHIL	0.2 L	%	1 - 2
MONOCYTES	4.2	%	2 - 10
PLATELET COUNT	1.91	lakh/cumm	1.500 - 4.500

HAEMOGLOBIN :- Method:-SLS Hemoglobin Methodology by Cell Counter. Interpretation:-Low-Anemia, High-Polycythemia.

MCV :- Method:- Calculation by sysmex. MCH :- Method:- Calculation by sysmex. MCHC :- Method:- Calculation bysysmex.

RBC COUNT :- Method:-Hydrodynamic focusing. Interpretation:-Low-Anemia, High-Polycythemia.

TLC (TOTAL WBC COUNT) :- Method: Optical Detector block based on Flowcytometry. Interpretation: High-Leucocytosis, Low-Leucopenia.

NEUTROPHILS :- Method: Optical detector block based on Flowcytometry LYMPHOCYTS :- Method: Optical detector block based on Flowcytometry EOSINOPHILS :- Method: Optical detector block based on Flowcytometry

MONOCYTES :- Method: Optical detector block based on Flowcytometry

BASOPHIL :- Method: Optical detector block based on Flowcytometry

PLATELET COUNT :- Method:-Hydrodynamic focusing method. Interpretation:-Low-Thrombocytopenia, High-Thrombocytosis.

HCT: Method:- Pulse Height Detection. Interpretation:-Low-Anemia, High-Polycythemia. NOTE: CH- CRITICAL HIGH, CL: CRITICAL LOW, L: LOW, H: HIGH

ESR (ERYTHROCYTE SEDIMENTATION RATE) 40 H mm/1st hr 0 - 15

**RESULT ENTERED BY: SUNIL EHS** 

Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

**Patient Name** Lab No Mrs. MADHU LATA MEENA 4032314 26/04/2024 10:11AM UHID 40013498 **Collection Date** 26/04/2024 10:15AM Age/Gender **Receiving Date** 30 Yrs/Female **Report Date** O-OPD **IP/OP Location** 26/04/2024 11:34AM **Referred By** Dr. EHS CONSULTANT **Report Status** Final Mobile No. 9414692856

Method:-Modified Westergrens. Interpretation:-Increased in infections, sepsis, and malignancy.

\*\*End Of Report\*\*

RESULT ENTERED BY : SUNIL EHS

**Patient Name** Mrs. MADHU LATA Lab No 4032314 **MEENA** UHID 40013498 **Sample Date** 26/04/2024 1:36PM 30 Yrs/Female Age/Gender Report Date 26/04/2024 2:54PM Prescribed By Dr. EHS CONSULTANT Bed No / Ward OPD **Referred By** Dr. EHS CONSULTANT **Report Status** Final Company Mediwheel - Arcofemi Health Care Ltd.

### **CYTOLOGY**

CYTOLOGY\*

Type of Specimen Pap smear (Conventional)

No. of smears examined Two

Satisfactory for evaluation.

Adequacy Adequate Endocervical cells Seen

Inflammation. Mild acute inflammation

Organisms Not seen

Epithelial cell abnormality Not seen

Others -

**Impression** Negative for intraepithelial lesion/ malignancy.

Note: Test marked as \* are not accredited by NABL

Bethesda2014

-----\*\* End Of Report \*\*------

Dr. ABHINAY VERMA

MBBS|MD|INCHARGE PATHOLOGY

0

# **DEPARTMENT OF RADIO DIAGNOSIS**

UHID / IP NO	40013498 (13209)	RISNo./Status:	4032314/
Patient Name:	Mrs. MADHU LATA MEENA	Age/Gender:	30 Y/F
Referred By:	Dr. EHS CONSULTANT	Ward/Bed No:	OPD
Bill Date/No :	26/04/2024 9:54AM/ OPSCR24- 25/2485	Scan Date :	
Report Date :	26/04/2024 11:57AM	<b>Company Name:</b>	Mediwheel - Arcofemi Health Care Ltd.

### **ULTRASOUND STUDY OF WHOLE ABDOMEN**

Liver: Normal in size & echotexture. No obvious significant focal parenchymal mass lesion

noted. Intrahepatic biliary radicals are not dilated. Portal vein is normal.

Gall Bladder: Multiple calculi seen within the lumen, largest measuring approx. 16mm. Wall

thickness is normal. CBD is normal.

**Pancreas:** Normal in size & echotexture.

**Spleen:** Normal in size & echotexture. No focal lesion seen.

Right Kidney: Normal in shape, size & location. Echotexture is normal. Corticomedullary

differentiation is maintained. No evidence of significant hydronephrosis or obstructive

calculus noted.

Left Kidney: Normal in shape, size & location. Echotexture is normal. Corticomedullary

differentiation is maintained. No evidence of significant hydronephrosis or obstructive

calculus noted.

Urinary Bladder: Normal in size, shape & volume. No obvious calculus or mass lesion is seen. Wall

thickness is normal.

Uterus: Normal in size, shape & anteverted in position. Minimal fluid seen within

endometrial cavity. No mass lesion is seen. Cervix is normal.

**Both ovaries:** Bilateral ovaries are normal in size, shape & volume. **Others:** No significant free fluid is seen in pelvic peritoneal cavity.

IMPRESSION: USG findings are suggestive of

• Cholelithiasis.

Minimal fluid within endometrial cavity.

Correlate clinically & with other related investigations.

DR. APOORVA JETWANI

**Incharge & Senior Consultant Radiology** 

MBBS, DMRD, DNB

Reg. No. 26466, 16307

# **DEPARTMENT OF CARDIOLOGY**

UHID / IP NO	40013498 (13209)	RISNo./Status:	4032314/
Patient Name:	Mrs. MADHU LATA MEENA	Age/Gender:	30 Y/F
Referred By:	Dr. EHS CONSULTANT	Ward/Bed No:	OPD
Bill Date/No :	26/04/2024 9:54AM/ OPSCR24- 25/2485	Scan Date :	
Report Date:	26/04/2024 12:35PM	<b>Company Name:</b>	Final

REFERRAL REASON: HEALTH CHECKUP

## 2D ECHOCARDIOGRAPHY WITH COLOR DOPPLER

### **M MODE DIMENSIONS: -**

Normal								Normal
IVSD	9.5	6-12mm			LVIDS	25.8	20-40mm	
LVIDD	46.7	32-57mm			LVPWS	15.4	mm	
LVPWD	10.4	6-12mm			AO	23.1	19-37mm	
IVSS	13.1	mm			LA	31.7	19-40mm	
LVEF	60-62	>55%			RA	-	mm	
DOPPLER MEASUREMENTS & CALCULATIONS:								
STRUCTURE	MORPHOLOGY	VELOCITY (m/s)			's)	GRADIENT		REGURGITATION
					(mmHg)			
MITRAL	NORMAL	E	1.05	e'	-	-		NIL
VALVE		A	0.68	E/e'	-			
TRICUSPID	NORMAL	E		0.65		-		MILD TR
VALVE		A		0.41		1		
			7.	0.41				
AORTIC	NORMAL	1.36				-		NIL
VALVE								
PULMONARY	NORMAL	0.89						NIL
VALVE						-		

## **COMMENTS & CONCLUSION: -**

- ALL CARDIAC CHAMBERS ARE NORMAL
- NO RWMA, LVEF 60-62%
- NORMAL LV SYSTOLIC FUNCTION
- NORMAL LV DIASTOLIC FUNCTION
- MILD TR, NO PAH, OTHER CARDIAC VALVES ARE NORMAL
- NO EVIDENCE OF CLOT/VEGETATION/PE
- INTACT IVS/IAS

## IMPRESSION: - MILD TR, NO PAH, NORMAL BI VENTRICULAR FUNCTIONS

**DR SUPRIY JAIN** MBBS, M.D., D.M. (CARDIOLOGY) INCHARGE & SR. CONSULTANT INTERVENTIONAL CARDIOLOGY

DR MEGHRAJ MEENA MBBS, CTCCM, SONOLOGIST MBBS, PGDCC, FIAE FICC, CONSULTANT PREV. CARDIOLOGY & INCHARGE CCU

DR ROOPAM SHARMA **CONSULTANT & INCHARGE** EMERGENCY, PREV. CARDIOLOGY(NIC) & WELLNESS **CENTER**